Reply

Dossarps, Denis; Bron, Alain M.; Koehrer, Philippe; Aho-Glélé, Ludwig S.; Creuzot‐Garcher, Catherine

doi:10.1016/j.ajo.2015.06.031

Cited by 5 publications

(4 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The incidence rate of endophthalmitis following anti-VEGF injection was 15.75 per 10,000 patients and 2.97 per 10,000 injections, which was similar to that reported by previous studies with large number of participants. [9,21] The annual incidences have been below 5.00 per 10,000 injections since 2011 although the number of intravitreal anti-VEGF injections has been increasing. The incidence of endophthalmitis was the highest in patients who received bevacizumab injections (3.64 per 10,000 injections).…”

Section: Discussionmentioning

confidence: 99%

“…In addition, we presumed outbreaks in center A and B since their higher incidence rate of endophthalmitis following intravitreal bevacizumab (See Supplementary endophthalmitis. [20,21] The use of two antibiotics to define endophthalmitis is quite reasonable since using diagnosis code to identify patients with endophthalmitis involves factors such as coding accuracy; this strategy, however, guarantees robustness of the study. Factors such as contamination, anti-VEGF drug lots, or batches contribute to endophthalmitis following anti-VEGF injection.…”

Section: Discussionmentioning

confidence: 99%

“…[19] This is a kind of mapping based on individual code system used for diagnosis, drug usage, laboratory results, and other clinical measurements using standard nomenclature system as follows: Systematized Nomenclature of Medicine, clinical terms (SNOMED CT) for diagnosis, RxNorm and RxNorm extension for drugs, and Logical Observation Identifiers Names and Codes (LOINC) for laboratory results and other clinical measurements. [20][21][22] This mapping process, developed by the working group of OHDSI community, is shared for mapping standardization. [23] We mapped the drugs used in our study to the RxNorm vocabulary (see Supplementary…”

Section: Omop Cdm and Vocabulary Mappingmentioning

confidence: 99%

See 2 more Smart Citations

Real-world incidence of endopthalmitis after intravitreal anti-VEGF injections in Korea: findings from the Common Data Model in ophthalmology

et al. 2021

View full text Add to dashboard Cite

OBJECTIVES The aim of this study was to evaluate the real-world incidence of endophthalmitis after intravitreal anti-vascular endothelial growth factor (VEGF) injections using data from the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM). METHODS Patients with endophthalmitis that developed within 6 weeks after intravitreal anti-VEGF injections were identified in 3 large OMOP CDM databases. RESULTS We identified 23,490 patients who received 128,123 intravitreal anti-VEGF injections. The incidence rates of endophthalmitis were 15.75 per 10,000 patients and 2.97 per 10,000 injections. The incidence rates of endophthalmitis for bevacizumab, ranibizumab, and aflibercept (per 10,000 injections) were 3.64, 1.39, and 0.76, respectively. The annual incidence has remained below 5.00 per 10,000 injections since 2011 despite the increasing number of intravitreal anti-VEGF injections. Bevacizumab presented a higher incidence rate for endophthalmitis than ranibizumab and aflibercept (incidence rate ratio, 3.17; p=0.021). CONCLUSIONS The incidence of endophthalmitis after intravitreal anti-VEGF injections has stabilized since 2011 despite the explosive increase in anti-VEGF injections. The off-label use of bevacizumab accounted for its disproportionately high incidence of endophthalmitis. The OMOP CDM, which includes off-label uses, laboratory data, and a scalable standardized database, could provide a novel strategy to reveal real-world evidence, especially in ophthalmology.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Omop Cdm and Vocabulary Mappingmentioning

confidence: 99%

See 1 more Smart Citation

Real-world incidence of endopthalmitis after intravitreal anti-VEGF injections in Korea: findings from the Common Data Model in ophthalmology

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The short half-life of brimonidine means that periodic intravitreal administration is needed to achieve therapeutic efficacy. However, repeated injection could lead to complications [5]. Therefore, development of sustained drug delivery systems is necessary.…”

mentioning

confidence: 99%

Monitoring New Long-Lasting Intravitreal Formulation for Glaucoma with Vitreous Images Using Optical Coherence Tomography

Rodrigo

Palomar

Montolío

et al. 2020

Preprint

View full text Add to dashboard Cite

Intravitreal injection is the gold standard therapeutic option for posterior segment pathologies, and long-lasting release is necessary to avoid reinjections. There is no effective intravitreal treatment for glaucoma or other optic neuropathies in daily practice, nor is there a non-invasive method to monitor drug levels in the vitreous. Here we show that a glaucoma treatment combining a hypotensive and neuroprotective intravitreal formulation (IF) of brimonidine-Laponite (BRI/LAP) can be monitored non-invasively using vitreous imaging captured with optical coherence tomography (OCT) over 24 weeks of follow-up. Qualitative and quantitative characterization was achieved by analysing the changes in vitreous (VIT) signal intensity, expressed as a ratio of retinal pigment epithelium (RPE) intensity. Vitreous hyperreflective aggregates mixed in the vitreous and tended to settle on the retinal surface. Relative intensity and aggregate size progressively decreased over 24 weeks in treated rat eyes as the BRI/LAP IF degraded. VIT/RPE relative intensity and total aggregate area correlated with brimonidine levels measured in the eye. The OCT-derived VIT/RPE relative intensity may be a useful and objective marker for non-invasive monitoring of BRI/LAP IF.

show abstract

Bactericidal activity of three different antiseptic ophthalmic preparations as surgical prophylaxis

Tognetto

Pastore

Guerin

et al. 2021

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

Purpose In the era of antibiotic resistance, there is an increased interest in antiseptic solutions that might represent a reliable option for ocular surface disinfection. The objective of this study is to compare for the first time three different antiseptic ophthalmic preparations to assess their in vitro antimicrobial activity. Methods The antiseptic activity of three commercial ophthalmic solutions, IODIM (povidone-iodine 0.6% in hyaluronic acid vehicle—Medivis, Catania, Italy), OZODROP (nanoemulsion with ozonated oil—concentration not specified—FBVision, Ophthalmic Pharmaceuticals, Rome, Italy), and DROPSEPT (chlorhexidine 0.02% and vitamin E 0.5% Tocopherol Polyethylene Glycol 1000 Succinate—TPGS, Sooft Italia, Montegiorgio, Italy), was tested in vitro on six reference strains by time-killing assays. Viable cells were evaluated after 1, 15, 30 min; 2, 6, and 24 h exposure by seeding 100 µl of the suspension (or appropriate dilutions) on LB agar or Sabouraud-dextrose agar. All plates were incubated at 37 °C for 24 h and evaluated by manually counting the colonies. Results IODIM solution showed a very rapid microbicidal activity: the number of viable cells for all the tested strains was under the detection limit (less than 10 CFU/ml) already after 1 min exposure, and this result was maintained at every incubation time. The rapid antimicrobial activity of povidone-iodine was not replicated when testing the other two antiseptics. Conclusions The study reports the great efficacy in reducing bacterial load in a very short time of povidone-iodine 0.6% compared with other antiseptic preparations.

show abstract

Reply

Cited by 5 publications

References 3 publications

Real-world incidence of endopthalmitis after intravitreal anti-VEGF injections in Korea: findings from the Common Data Model in ophthalmology

Real-world incidence of endopthalmitis after intravitreal anti-VEGF injections in Korea: findings from the Common Data Model in ophthalmology

Monitoring New Long-Lasting Intravitreal Formulation for Glaucoma with Vitreous Images Using Optical Coherence Tomography

Bactericidal activity of three different antiseptic ophthalmic preparations as surgical prophylaxis

Contact Info

Product

Resources

About